Capital World Investors Reduces Stake in argenex SE $ARGX

Capital World Investors lowered its holdings in argenex SE (NASDAQ:ARGX) by 2.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,916,234 shares of the company’s stock after selling 43,270 shares during the quarter. Capital World Investors owned approximately 3.10% of argenex worth $1,611,433,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Oppenheimer & Co. Inc. lifted its holdings in argenex by 2.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock worth $372,000 after buying an additional 12 shares during the period. Valeo Financial Advisors LLC lifted its holdings in argenex by 0.9% in the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after buying an additional 12 shares during the period. Sound View Wealth Advisors Group LLC lifted its holdings in argenex by 3.4% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock worth $292,000 after buying an additional 13 shares during the period. Allworth Financial LP lifted its holdings in argenex by 12.7% in the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after buying an additional 13 shares during the period. Finally, Portside Wealth Group LLC lifted its holdings in argenex by 2.8% in the 3rd quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock worth $430,000 after buying an additional 16 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several research analyst reports. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Guggenheim raised their target price on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research note on Friday, May 8th. HC Wainwright raised their target price on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Deutsche Bank Aktiengesellschaft upgraded argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Finally, Oppenheimer lowered their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research note on Thursday, April 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus target price of $1,019.50.

argenex Stock Up 5.8%

ARGX opened at $891.32 on Friday. The stock has a market cap of $55.43 billion, a PE ratio of 39.68, a PEG ratio of 1.36 and a beta of 0.47. The business has a 50 day moving average of $794.90 and a 200-day moving average of $813.42. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. Equities analysts anticipate that argenex SE will post 26.25 EPS for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.